Introduction de Novacyt sur NYSE Alternext


Paris – 12 October 2012– NYSE Euronext (NYX) today announced the listing on NYSE Alternext in Paris of Novacyt, a specialist in next-generation cytology solutions.

Founded in 2006, Novacyt designs, develops and markets innovative liquid-based cytology solutions with applications in molecular biology. The company’s NovaPrep® Processor System uses fully patented technology to optimise detection of precancerous and cancerous lesions. Novacyt is present in France and on international markets through a network of 13 distributors. Its products carry the EC-IVD label in Europe and the SFDA label in China, and it has received a marketing authorisation for Russia.

Novacyt (ticker: ALNOV) was listed through admission to trading of 2,389,335 existing shares and 318,127 new shares issuedunder a Global Offering.[1] The Global Offering raised a total of €2.6 million, with theadmission and issue price of shares set at €8.10 per share. Market capitalisation stood at around €22 million on the day of listing.

“We are delighted to welcome Novacyt to NYSE Alternext, where listing will enable it to pursue development of new products to help detect cancers in a variety of countries,” said Marc Lefèvre, Head of European Business Development and Client Coverage at NYSE Euronext. “Backed by our trading platform and very wide network of members, NYSE Alternext our market designed especially for small and mid-size companies offers both listed companies and investors access to a unique pool of liquidity.”

Eric Peltier, Chairman and CEO of Novacyt added: “We would like to thank all our shareholders for their trust, which has enabled us to take this major step. They will now be able to accompany us as our R&D programmes develop new products to round out our existing range and improve cancer detection and diagnostics.”

In seven years, €2.7 billion has been raised on NYSE Alternext, half through secondary issues, by companies from Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their marketcapitalisation totals €6 billion. Today 183 companies are listed on NYSE Alternext.

[1]The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.


Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.